(TheNewswire)
London, ON – TheNewswire – February 2 2021 - On the heels ofrecent partnership interest and conference presentations , Global News London’sJess Brady took time took time to truly explore the pertinence of Sernova’sregenerative cell pouch technology.
The recent news coverage further validates Sernova’sadvancements in conjiunction with a generalpublic and investor / media intetrest in all things medical.
We strongly urge shareholders toshare this interview via social media, as it offers a great overviewof how Sernova’s break-through technology works and its goals;
Play 980 CFPL London – runs8:38
London, Ontario is the home of BantingHouse , the home of Dr. Fredrick Banting , the man w ho invented insulin 100 years ago.
Sernova Corp. isdeveloping regenerative medicine therapeutic technologies using amedical device and immune protected therapeutic cells (i.e., humandonor cells, corrected human cells and stem cell-derived cells) toimprove the treatment and quality of life of people with chronicmetabolic diseases such as insulin-dependent diabetes, blood disordersincluding hemophilia, and other diseases treated through replacementof proteins or hormones missing or in short supply within the body.For more information, please visit www.sernova.com .
FOR FURTHER INFORMATION, PLEASE CONTACT:
Dominic Gray
Sernova Corp.
Tel: (519) 858-5126
dominic.gray@sernova.com
FORWARD-LOOKING INFORMATION
This release contains statements that, to the extent they are notrecitations of historical facts, may constitute “forward-lookingstatements” that involve various risks, uncertainties, andassumptions, including, without limitation, statements regarding theprospects, plans, and objectives of the company. Wherever possible,but not always, words such as "expects", "plans","anticipates", "believes", "intends","estimates", "projects", "potential for"and similar expressions, or that events or conditions"will", "would", "may","could" or "should" occur are used to identifyforward-looking statements. These statements reflect management’sbeliefs with respect to future events and are based on informationcurrently available to management on the date such statements weremade. Many factors could cause Sernova’s actual results,performances or achievements to not be as anticipated, estimated orintended or to differ materially from those expressed or implied bythe forward-looking statements contained in this news release. Suchfactors could include, but are not limited to, the company’s abilityto secure additional financing and licensing arrangements onreasonable terms, or at all; ability to conduct all requiredpreclinical and clinical studies for the company’s Cell Pouch Systemand/or related technologies, including the timing and results of thosetrials; ability to obtain all necessary regulatory approvals, or on atimely basis; ability to in-license additional complementarytechnologies; ability to execute its business strategy andsuccessfully compete in the market; and the inherent risks associatedwith the development of biotechnology combination products generally.Many of the factors are beyond our control, including those caused by,related to, or impacted by the novel coronavirus pandemic. Investorsshould consult the company’s quarterly and annual filings availableon www.sedar.com for additional information on risks and uncertaintiesrelating to the forward-looking statements. Sernova expresslydisclaims any intention or obligation to update or revise anyforward-looking statements, whether as a result of new information,future events or otherwise.
Copyright (c) 2021 TheNewswire - All rights reserved.